Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
Eastern Cooperative Oncology Group
NRG Oncology
Eastern Cooperative Oncology Group
R-Pharm
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Radiation Therapy Oncology Group
Incyte Corporation
Bristol-Myers Squibb
Azienda USL Reggio Emilia - IRCCS
Pfizer
Merck Sharp & Dohme LLC
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Ludwig-Maximilians - University of Munich
AVEO Pharmaceuticals, Inc.